Clinical effects of hydration, supplementary vitamins, and trace elements during end-of-life care for cancer patients

Pérez-Camargo, Dana Aline; Allende-Pérez, Silvia Rosa; Rivera-Franco, Mónica M.; Urbalejo-Ceniceros, Víctor Itaí; Sevilla-González, María de la Luz; Arzate-Mireles, Cinthya E.; Copca-Mendoza, Erika Thalia

doi:10.20960/nh.04446

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Pérez-Camargo et al reported a RCT comparing low-volume CAH (500 ml/day) with or without supplemental vitamins and trace elements in clinically dehydrated patients with various symptoms (i.e. pain, fatigue, anorexia, chronic nausea, somnolence, insomnia, dyspnoea, “lack of overall wellbeing”, anxiety, depression) [ 37 ]. The trial lasted for 4 weeks, and patients in the CAH alone arm reported no improvement in symptoms, whilst patients in the CAH with vitamins and trace elements reported improvement in a number of symptoms (and a statistically significant improvement in pain and anorexia).…”

Section: Introductionmentioning

confidence: 99%

Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/guidance on the use of clinically assisted hydration in patients with advanced cancer

Hayes,

Bruera,

Crawford

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

Purpose The provision of clinically assisted hydration (CAH) in patients with advanced cancer is controversial, and there is a paucity of specific guidance and so a diversity in clinical practice. Consequently, the Palliative Care Study Group of the Multinational Association of Supportive Care in Cancer (MASCC) formed a sub-group to develop evidence-based guidance on the use of CAH in patients with advanced cancer. Methods This guidance was developed in accordance with the MASCC Guidelines Policy. A search strategy for Medline was developed, and the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials were explored for relevant reviews/trials, respectively. Results Due to the paucity of evidence, the sub-group was not able to develop a prescribed guideline, but was able to generate a number of “expert opinion statements”: these statements relate to assessment of patients, indications for CAH, contraindications for CAH, procedures for initiating CAH, and reassessment of patients. Conclusions This guidance provides a framework for the use of CAH in advanced cancer, although every patient requires individualised management.

show abstract

Section: Introductionmentioning

confidence: 99%